Golfyeti,

I am not sure of the method used by Resverlogix and their collaborators for the measurment of plasma amyloid-beta 40 levels in their Phase 1a and Phase 2 ASSERT trials. However, in the news release for the Phase 1a, it states "The analysis of the plasma markers for Alzheimer’s disease was performed by Dr. D. Larry Sparks, Senior Scientist and Head of the Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute in Sun City, Arizona......For 21 years, Sun Health Research Institute, part of nonprofit Banner Health, has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer’s disease, Parkinson’s disease, arthritis and prostate cancer. The institute, together with its Arizona Alzheimer’s Consortium partners, has been designated by the National Institutes of Health as one of just 31 Alzheimer’s disease Centers in the nation." It's not clear to me from the ASSERT news release if the now late Dr. Sparks was involved in the Phase 2 measurements. Seems that more recent blood tests look at ratios of AB-40 to AB-42, or APP to AB-42, not just absolute AB-40 levels as reported in the Resverlogix trials.

BDAZ